Michael J. Kovacs

4.4k total citations · 1 hit paper
58 papers, 3.0k citations indexed

About

Michael J. Kovacs is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Michael J. Kovacs has authored 58 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Internal Medicine, 22 papers in Cardiology and Cardiovascular Medicine and 15 papers in Hematology. Recurrent topics in Michael J. Kovacs's work include Venous Thromboembolism Diagnosis and Management (32 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (11 papers). Michael J. Kovacs is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (32 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (11 papers). Michael J. Kovacs collaborates with scholars based in Canada, United States and New Zealand. Michael J. Kovacs's co-authors include Oscar Ballester, Allan Lipton, Alan Keller, Alan Lichtenstein, Dirk J. Reitsma, James R. Berenson, Robert Knight, Meletios Α. Dimopoulos, Joseph F. Simeone and John J. Seaman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michael J. Kovacs

55 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1996 780 citations James R. Berenson, Alan Lichtenstein et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Michael J. Kovacs

Since Specialization

Citations

This map shows the geographic impact of Michael J. Kovacs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Kovacs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Kovacs more than expected).

Fields of papers citing papers by Michael J. Kovacs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Kovacs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Kovacs. The network helps show where Michael J. Kovacs may publish in the future.

Co-authorship network of co-authors of Michael J. Kovacs

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Kovacs. A scholar is included among the top collaborators of Michael J. Kovacs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Kovacs. Michael J. Kovacs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism 2023 ·Journal of Thrombosis and Haemostasis ·Lucia Caiano, Michael J. Kovacs, Alejandro Lazo‐Langner, David R. Anderson, Susan R. Kahn, Vinay Shah, Scott Kaatz, (unknown), Sam Schulman, Isabelle Chagnon, Ranjeeta Mallick, Marc Rodger, Philip S. Wells	3
2	A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3 2022 ·Blood ·Michael J. Kovacs, Philip S. Wells, Marc Rodger, Marc Carrier, Erik Yeo, (unknown), Alejandro Lazo‐Langner	9
3	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial 2021 ·BMJ ·Michael J. Kovacs, Philip S. Wells, David R. Anderson, Alejandro Lazo‐Langner, Clive Kearon, Shannon M. Bates, Mark Blostein, Susan R. Kahn, Sam Schulman, Elham Sabri, Susan Solymoss, Tim Ramsay, Erik Yeo, Marc Rodger	44
4	Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes 2021 ·Thrombosis Research ·Eri Kawata, (unknown), (unknown), Martha Louzada, Michael J. Kovacs, Alejandro Lazo‐Langner	12
5	Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort 2016 ·Thrombosis Research ·Marc Rodger, (unknown), Susan R. Kahn, Philip Wells, David R. Anderson, Isabelle Chagnon, Grégoire Le Gal, Esteban Gándara, Susan Solymoss, Elham Sabri, Judy Kovacs, Michael J. Kovacs	26
6	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin 2016 ·Thrombosis and Haemostasis ·(unknown), Alejandro Lazo‐Langner, Michael J. Kovacs, Erik Yeo, Terri Schnurr, Sam Schulman, Mark Crowther, Kochawan Boonyawat	4
7	Absolute Cerebral Blood Flow Infarction Threshold for 3-Hour Ischemia Time Determined with CT Perfusion and 18F-FFMZ-PET Imaging in a Porcine Model of Cerebral Ischemia 2016 ·PLoS ONE ·(unknown), Christopher D. d’Esterre, Laura Morrison, Neil Cockburn, Michael J. Kovacs, Ting‐Yim Lee	14
8	Screening of Patients with Idiopathic Venous Thromboembolism for Paroxysmal Nocturnal Hemoglobinuria Clones 2015 ·Thrombosis Research ·Alejandro Lazo‐Langner, Michael J. Kovacs, (unknown), Fatimah Al‐Ani, Michael Keeney, Martha Louzada, Ian Chin‐Yee	6
9	Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study 2014 ·Blood ·Matthew Kang, (unknown), (unknown), Michael J. Kovacs, Alejandro Lazo‐Langner	86
10	Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials 2010 ·Haematologica ·Alejandro Lazo‐Langner, (unknown), Walter Ageno, Michael J. Kovacs	35
11	Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram 2009 ·Journal of Thrombosis and Haemostasis ·Alejandro Lazo‐Langner, (unknown), Michael J. Kovacs	18
12	Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischaemic preconditioning 2007 ·Cardiovascular Research ·Rita Papp, Mónika Gönczi, Michael J. Kovacs, György Seprényi, Á Végh	40
13	Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients 2005 ·Thrombosis and Haemostasis ·Mark Levine, Michael Keeney, Karen MacKinnon, Agnes Lee, Michael J. Kovacs	14
14	Fondaparinux: A potential new therapy for HIT 2005 ·Hematology ·Kevin H.M. Kuo, Michael J. Kovacs	34
15	Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism 2000 ·New England Journal of Medicine ·Patrick Brill-Edwards, Jeffrey S. Ginsberg, Michael Gent, Jack Hirsh, Robert Burrows, Clive Kearon, William Geerts, Michael J. Kovacs, Jeffrey I. Weitz, Kristine Robinson, Renaud Whittom, (unknown)	255
16	Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial 2000 ·The Lancet ·Mark Crowther, Jim A. Julian, (unknown), James D. Douketis, Michael J. Kovacs, (unknown), Terri Schnurr, Joanne McGinnis, Michael Gent, Jack Hirsh, (unknown)	126
17	Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin 1999 ·Clinical & Laboratory Haematology ·Michael J. Kovacs, Michael Keeney, Karen MacKinnon, Eleanor Boyle	61
18	Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy 1997 ·Obstetrics and Gynecology ·(unknown), Michael J. Kovacs	20
19	Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma breakdown → 1996 ·New England Journal of Medicine ·James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios Α. Dimopoulos, (unknown), (unknown), Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hilary Blacklock, Richard H. Bell, Joseph F. Simeone, Dirk J. Reitsma, (unknown), John J. Seaman, Robert Knight	780
20	Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli 0157:H7 1990 ·The American Journal of Medicine ·Michael J. Kovacs, Janet Roddy, Sylvie Grégoire, D. William Cameron, (unknown), Jeanne Drouin	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact